## **PARACETAMOL – For Patent Ductus Arteriosus**

Trade Name	Paracetamol Kabi (Fresenius Kabi NZ)
Class	Antipyretic and analgesic.
Mechanism of Action	Patent ductus arteriosus: Potential mechanisms include inhibition of central prostaglandin synthesis and inhibition of the cyclooxygenase (COX) isoenzyme, particularly the COX-2 isoform.
Indications	Haemodynamically significant patent ductus arteriosus
	<ol> <li>Firstline management if there are contraindications to using indomethacin (the standard firstline treatment)</li> <li>Secondline management after an indomethacin course if more indomethacin is undesirable</li> <li>Use before 28 days of age</li> <li>Limit to one course only ie: max of 6 days treatment</li> </ol>
Contraindications	Hypersensitivity to paracetamol Hepatic failure G6PD deficiency can lead to haemolytic anaemia
Precautions	Caution in renal failure Caution with hepatocellular insufficiency Dehydration Clearance falls with unconjugated hyperbilirubinaemia
Supplied As	IV:10 mg/mL in 100mL glass vials Oral: 120 mg/ 5 mL
Dilution	IV: Can be diluted in 0.9% saline and 5% dextrose if needed Oral: Nil
Dosage/Interval	15mg/kg/dose 6 hourly for 3-6 days
	Oral or IV but <b>preference to give iv</b> if access is possible
Administration	IV: Infusion over 15 minutes  Oral: can be given anytime in regards to feeds
Intravenous Dose Compatible With	Solution: Sodium chloride 0.9% and 5% & 10% dextrose Terminal Y-site: Cefazolin, cefoxitin, dexamethasone 10 mg/mL, dexmedetomidine, diphenhydramine 50 mg/mL, fentanyl 50 mcg/mL, gentamicin, heparin 100 units/mL, hydrocortisone 50 mg/mL, hydromorphone 4 mg/mL, ketorolac 15 mg/mL, labetalol, lactated Ringer solution, lidocaine 20 mg/mL, lorazepam 0.5 mg/mL, magnesium sulphate, mannitol 150 mg/mL (15%), methylprednisolone 125 mg/mL, methylprednisolone, metoclopramide 5 mg/mL, midazolam 5 mg/mL, morphine 15 mg/mL, nalbuphine 20 mg/mL, ondansetron 2 mg/mL, pentoxifylline, piperacillin/tazobactam, potassium chloride 0.1 mEg/mL, TPN, vancomycin.

Paracetamol for PDA

Printed copies are <u>not</u> controlled and may not be the current version in use

	<del> </del>
Intravenous Dose Incompatible With	Aciclovir, atropine, chlorpromazine, diazepam, metronidazole, phenobarbital, phenytoin, propofol.
	Information on compatibility of IV paracetamol with other medicines is relatively limited.
	There is no information on compatibility of paracetamol with alprostadil, amoxicillin, cefotaxime, dopamine, dobutamine, flucloxacillin, erythromycin, lipid or sildenafil. If any of these medicines are prescribed in combination with paracetamol it is recommended to use a separate line and consult pharmacist for further advice.
Interactions	Increased rate of metabolism of paracetamol when given in combination with carbamazepine, phenobarbital, phenytoin, rifampicin.
	Flucloxacillin + paracetamol may predispose to metabolic acidosis especially if patient has renal impairment
	Isoniazid + paracetamol may increase risk of formation of toxic paracetamol metabolites
	Zidovudine + paracetamol may increase risk of bone marrow suppression
Monitoring	Heart scan after 3 days to assess the PDA:
	<ul> <li>If PDA is closed then stop the course</li> <li>If PDA is open and needs ongoing treatment check LFT to ensure it is safe to continue with a 6 day course</li> <li>No studies have measured trough levels so no routine levels are not required.</li> </ul>
Stability	IV: If diluted, administer within 30 minutes. Vials are preservative free and are for single use only.
Storage	IV: Do not store in the fridge Single use only Complete infusion within 1 hour of opening the vial
Adverse Reactions	Pain at injection site Rash, fever, bone marrow depression Beware of accumulation if used regularly Hepatotoxicity in neonates rare. Use with caution in hepatic or renal failure Overdose: hepatotoxicity, renal tubular acidosis, metabolic acidosis, encephalopathy. Monitor LFT and coag profile and treat with n-acetylcysteine
Metabolism	100% bioavailability.  Metabolised in the liver by conjugation and metabolism by cytochrome P450. Excreted in the urine 90%
Comments	Licensed for use in term newborns.

March 2022

	Safety and efficacy data have not been established on preterm infants
	See Neofax for treatment of serious overdose
	Probably works better when given as first line treatment for PDA but may be given after Indomethacin treatment has failed
	Comparable efficacy to indomethacin and ibuprofen and more favourable adverse effect profile
References	<ol> <li>Medsafe data sheet</li> <li>*Princess Margaret Hospital Perth. Paracetamol protocol June 2008</li> <li>Allegaert K et al. IV paracetamol pharmacokinetics in term + preterm infants. European J Clin Pharm 2004 60:191-7</li> <li>Allegaert K et al. Pharmacokinetics of single dose iv propacetamol in neonates: effect of gestational age. Arch Dis Fetal Neonatal Ed 2004;89:F25-28.</li> <li>Palmer GM et al.IV acetaminophen pharmacokinetics in neonates after multiple doses. BJA 2008;101:523-30.</li> <li>Anderson BJ et al. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. European J Clin Pharm 2001;57:559-69.</li> <li>Bartocci M, Lundeberg S. IV paracetamol: the "Stockholm protocol" for postoperative analgesia of term and preterm neonates. Pediatr Anaesthesia 2007:17, 111-21</li> <li>Allegaert K et al. Not al iv paracetamol formulations are created equal Pediatr Anaesthesia 2007:17, 809-18.</li> <li>Anderson BJ, Allegaert K. IV neonatal paracetamol dosing: the magic of 10 days. Pediatr Anaesthesia 2009:289-95.</li> <li>Jasani B et al. Evidense based use of acetaminophen for hemodynamically significant ductus arteriosus in preterm infants. Seminars in perinatology. 2018: Jun; 42(4): 243-252.</li> <li>King Edward Memorial Hospital and Perth ChidIren's Hospital Neonatalogy. Neonatal Paracetamol Guidline. Accessed 1.9.18</li> <li>Royal hospital for Women, Sydney. Paracetamol Guidline. Accessed 1.9.18</li> <li>Ohlsson A. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Systemic Review. 2018 April 6: 4.</li> <li>Trissel IV compatibilities in www.micromedexsolution.com</li> </ol>
	15. Neofax in <u>www.micromedexsolutions.com</u>
Updated By	A Lynn, R Sinclair, B Dixon A Lynn, M Wallenstein A Lynn, B Robertshawe and interactions)  Oct 2018 (new profile for PDA treatment) Jan 2021 – incompatibilities clearer March 2022 (- brand update, compatibilities